Opinion|Videos|June 6, 2024
Community Physician Voices: Exploring Management Options for a College-Age Patient with Vitiligo
Author(s)Rocco Serrao, MD, FAAD
Dr Serrano, shares insights on the panel’s advice given to their patients with vitiligo who have achieved remission through treatment with ruxolitinib, while also addressing the challenges of navigating payer coverage for vitiligo treatments and strategies for dealing with coverage denials.
Advertisement
Episodes in this series
- What guidance do you provide to patients with vitiligo upon achieving remission with ruxolitinib treatment?
- How do you counsel them regarding ongoing management?
- Do you advise continuing or discontinuing treatment in pigmented versus depigmented areas?
- If faced with this patient, would you have approached treatment in the same manner?
- When it comes to topical ruxolitinib, is it generally covered by insurance, or have you encountered instances where patients had difficulty securing coverage for this treatment?
- How do you navigate such situations?
- Could you share insights on the process of obtaining insurance authorization for vitiligo treatments like topical ruxolitinib?
- What are the typical steps involved, and how do you assist patients in this process?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
